TG Therapeutics, Inc.
IT ˙ BIT ˙ US88322Q1085
34,00 € 0,00 (0,00%)
2026-06-05
DEL PRIS
SecurityIT:1TGTX / TG Therapeutics, Inc.
InstitutionProfund Advisors Llc
Latest Disclosed Ownership76,039 shares
Latest Disclosed Value $ 2,526,016
Profund Advisors Llc reports 1.64% increase in ownership of 1TGTX / TG Therapeutics, Inc.

On April 24, 2026 - Profund Advisors Llc filed a 13F-HR form disclosing ownership of 76,039 shares of TG Therapeutics, Inc. (IT:1TGTX) valued at $2,103,239 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 74,814 shares of TG Therapeutics, Inc.. This represents a change in shares of 1.64% during the quarter. The current value of the position is $2,585,326 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F TG THERAPEUTICS COM 88322Q108 76,039 1,225 1.64 2,526 13.27 0.0927
2026-02-06 2025-12-31 13F TG THERAPEUTICS COM 88322Q108 74,814 24,569 48.90 2,230 22.87 0.0678
2025-11-06 2025-09-30 13F TG THERAPEUTICS COM 88322Q108 50,245 5,803 13.06 1,815 13.51 0.0590
2025-08-07 2025-06-30 13F TG THERAPEUTICS COM 88322Q108 44,442 2,057 4.85 1,599 -4.31 0.0576
2025-05-08 2025-03-31 13F TG THERAPEUTICS COM 88322Q108 42,385 -25,638 -37.69 1,671 -18.37 0.0726
2025-02-14 2024-12-31 13F TG THERAPEUTICS COM 88322Q108 68,023 -3,618 -5.05 2,047 22.21 0.0747
2024-11-14 2024-09-30 13F TG THERAPEUTICS COM 88322Q108 71,641 9,025 14.41 1,676 50.49 0.0634
2024-08-13 2024-06-30 13F TG THERAPEUTICS COM 88322Q108 62,616 -23,180 -27.02 1,114 -14.65 0.0413
2024-05-08 2024-03-31 13F TG THERAPEUTICS COM 88322Q108 85,796 -7,693 -8.23 1,305 -18.30 0.0508
2024-02-14 2023-12-31 13F TG THERAPEUTICS COM 88322Q108 93,489 -50,092 -34.89 1,597 33.00 0.0686
2023-11-13 2023-09-30 13F TG THERAPEUTICS COM 88322Q108 143,581 87,133 154.36 1,200 -14.41 0.0664
2023-08-10 2023-06-30 13F TG THERAPEUTICS COM 88322Q108 56,448 -33,956 -37.56 1,402 3.16 0.0752
2023-05-12 2023-03-31 13F TG THERAPEUTICS COM 88322Q108 90,404 90,404 1,360 0.0840
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.